Nurix Therapeutics Gross Profit

Nurix Therapeutics posts a gross profit of $-57M as of May 2026. That compares with $40M in the prior-year period — down 241.8% year over year. That is below the Healthcare sector average of $67B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Nurix Therapeutics's gross profit was $40M. The latest reading is $-57M — a 241.8% year-over-year decrease (period ending May 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a gross profit near $67B is typical. Nurix Therapeutics's $-57M is lower that level. That is roughly 100.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of Nurix Therapeutics's financial statement story. At $-57M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for NRIX's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $67B), and (3) consistency with growth and profitability. This page covers the first two; Nurix Therapeutics's other metric pages and overview cover the third.